Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026. "Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.

PRNewsWire • Jun 15, 2026

20 growth stocks priced as value stocks

A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight financial services companies, five healthcare names and four in the information technology sector.

Market Watch • Jun 15, 2026

Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 10, 2026

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Investors need to pay close attention to HALO stock based on the movements in the options market lately.

Zacks Investment Research • May 26, 2026

Halozyme Therapeutics: Royalty King

Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028 guidance, and announced a new $1 billion share repurchase program. HALO trades at a significant discount to historical and sector valuations, despite maintaining >75% gross margins and strong free cash flow.

Seeking Alpha • May 20, 2026

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.

Zacks Investment Research • May 12, 2026

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.

MarketBeat • May 12, 2026

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 12, 2026

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 million Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30% Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% - 35% Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1 Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1 SAN DIEGO, May 11, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2026, and provided an update on its recent corporate activities. "I am pleased to announce our new $1 billion share repurchase program and that we project to repurchase at least $400 million in 2026, which is a reflection of our strong cash generation and confidence in the long-term value and durability of our business.

PRNewsWire • May 11, 2026

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.11 per share a year ago.

Zacks Investment Research • May 11, 2026